(Q57697033)

7

0 references

author name string

Qian Yang

1

0 references

David Fedida

2

0 references

Hongjian Xu

3

0 references

Lupei Du

5

0 references

Xiaojian Wang

6

0 references

Qidong You

Drug discoveries towards Kv1.5 potassium channel.

8

0 references

publication date

10 June 2010

0 references

published in

ChemMedChem

0 references

volume

5

0 references

page(s)

1353-1358

0 references

issue

8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

How does consensus scoring work for virtual library screening? An idealized computer experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

Acute management of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Management of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Drug discovery for heart failure: a new era or the end of the pipeline?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

A benefit-risk assessment of class III antiarrhythmic agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Strategies for atrial fibrillation therapy: focusing onIKurpotassium channel

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

The moving parts of voltage-gated ion channels

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

The mechanism of atrial antiarrhythmic action of RSD1235.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Vernakalant: RSD 1235, RSD-1235, RSD1235

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Atrial fibrillation: from ion channels to bedside treatment options

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Modeling the binding modes of Kv1.5 potassium channel and blockers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Discovery of the first SecA inhibitors using structure-based virtual screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Structure-Based Discovery and Experimental Verification of Novel AI-2 Quorum Sensing Inhibitors againstVibrio harveyi

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

The effect of different electrostatic potentials on docking accuracy: A case study using DOCK5.4

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Development and validation of a modular, extensible docking program: DOCK 5.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Empirical scoring functions. II. The testing of an empirical scoring function for the prediction of ligand-receptor binding affinities and the use of Bayesian regression to improve the quality of the model.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Deciphering common failures in molecular docking of ligand-protein complexes.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Detailed analysis of scoring functions for virtual screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Gaussian docking functions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Computational studies of H5N1 hemagglutinin binding with SA-α-2, 3-Gal and SA-α-2, 6-Gal

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

VMD: visual molecular dynamics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

The Amber biomolecular simulation programs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

Satisfying hydrogen bonding potential in proteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021

The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000162

7 January 2021